ipilimumab,nivolumab,225ac-psma-617,177lu-psma-617
novartis,bms
['psma-617 ', 'crpc', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'nivolumab', 'nivo', 'ipilimumab', '177lu,psma,617', 'anzup 2001']
#evolution phase ii study of radionuclide 177lu-psma-617 vs 177lu-psma-617 in combination with ipilimumab and nivolumab for men with #mcrpc (anzup 2001). presented by . #gu23 written coverage by &gt; 
Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology